Analysis of PD‐L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas. Issue 6 (17th October 2019)
- Record Type:
- Journal Article
- Title:
- Analysis of PD‐L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas. Issue 6 (17th October 2019)
- Main Title:
- Analysis of PD‐L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas
- Authors:
- Jha, Prerana
Manjunath, Niveditha
Singh, Jyotsna
Mani, Kalaivani
Garg, Ajay
Kaur, Kavneet
Sharma, Mehar C.
Raheja, Amol
Suri, Ashish
Sarkar, Chitra
Suri, Vaishali - Abstract:
- Abstract : Diffuse midline gliomas (DMGs) are rare and devastating tumors with limited therapeutic options. Programmed death‐ligand 1 (PD‐L1) expression represents a potential predictive biomarker for immunotherapy. One hundred and twenty‐six DMGs (89 adult and 37 pediatric) were assessed for immune profile (PD‐L1, cluster of differentiation (CD3, CD8) and genetic markers (mutation in 27th amino acid of histone H3 (H3K27M), alpha thalassemia/mental retardation syndrome X‐linked (ATRX), isocitrate dehydrogenase 1 (IDH1), p53) by immunohistochemistry. Sanger sequencing was done for IDH1 and H3K27M. The thalamus was the commonest site. Four molecular subgroups of DMGs were identified. H3K27M mutation was more frequent in children ( P = 0.0001). The difference in median overall survival (OS) was not significant in any of the four molecular subgroups ( P > 0.05). PD‐L1 expression was significantly higher in H3K27M/IDH1 double‐negative adult glioblastomas (GBMs) ( P = 0.002). Strong PD‐L1 expression was more frequent in grade IV tumors and thalamic location, although the difference was not significant ( P = 0.14 and P = 0.19 respectively). Positive PD‐L1 expression was significantly associated with high tumor‐infiltrating lymphocytes count ( P < 0.05). There was no significant difference in median OS in PD‐L1‐positive versus negative cases among four genetic subgroups ( P > 0.05). On univariate analysis, there was no direct correlation of PD‐L1 with any genetic alteration, exceptAbstract : Diffuse midline gliomas (DMGs) are rare and devastating tumors with limited therapeutic options. Programmed death‐ligand 1 (PD‐L1) expression represents a potential predictive biomarker for immunotherapy. One hundred and twenty‐six DMGs (89 adult and 37 pediatric) were assessed for immune profile (PD‐L1, cluster of differentiation (CD3, CD8) and genetic markers (mutation in 27th amino acid of histone H3 (H3K27M), alpha thalassemia/mental retardation syndrome X‐linked (ATRX), isocitrate dehydrogenase 1 (IDH1), p53) by immunohistochemistry. Sanger sequencing was done for IDH1 and H3K27M. The thalamus was the commonest site. Four molecular subgroups of DMGs were identified. H3K27M mutation was more frequent in children ( P = 0.0001). The difference in median overall survival (OS) was not significant in any of the four molecular subgroups ( P > 0.05). PD‐L1 expression was significantly higher in H3K27M/IDH1 double‐negative adult glioblastomas (GBMs) ( P = 0.002). Strong PD‐L1 expression was more frequent in grade IV tumors and thalamic location, although the difference was not significant ( P = 0.14 and P = 0.19 respectively). Positive PD‐L1 expression was significantly associated with high tumor‐infiltrating lymphocytes count ( P < 0.05). There was no significant difference in median OS in PD‐L1‐positive versus negative cases among four genetic subgroups ( P > 0.05). On univariate analysis, there was no direct correlation of PD‐L1 with any genetic alteration, except H3K27M mutation ( P = 0.01). CD3 infiltration was similar in both adults and pediatric ages (84.3% and 78.4%, respectively) while CD8 expression was significantly greater in adults compared to children (74.1% vs 37.8%, P = 0.0001). This is the first comprehensive analysis highlighting molecular and immune profiles of DMGs. Despite molecular and clinicopathological diversity, overall survival in DMGs remains dismal. Multicentric studies with larger numbers of cases should be undertaken for stratifying DMGs according to their age, immune and molecular profiles, to develop effective immunotherapies. … (more)
- Is Part Of:
- Neuropathology. Volume 39:Issue 6(2019)
- Journal:
- Neuropathology
- Issue:
- Volume 39:Issue 6(2019)
- Issue Display:
- Volume 39, Issue 6 (2019)
- Year:
- 2019
- Volume:
- 39
- Issue:
- 6
- Issue Sort Value:
- 2019-0039-0006-0000
- Page Start:
- 413
- Page End:
- 424
- Publication Date:
- 2019-10-17
- Subjects:
- GBM -- midline glioma -- PD‐L1 -- pediatric -- T cell
Nervous system -- Diseases -- Periodicals
Nervous system -- Pathophysiology -- Periodicals
616.8047 - Journal URLs:
- http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=neu ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/neup.12594 ↗
- Languages:
- English
- ISSNs:
- 0919-6544
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6081.513800
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 12458.xml